201 related articles for article (PubMed ID: 38063879)
21. Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs.
Mossadeq S; Shah R; Shah V; Bagul M
AAPS PharmSciTech; 2022 Nov; 24(1):2. PubMed ID: 36416999
[TBL] [Abstract][Full Text] [Related]
22. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
23. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Ramasamy S; Subbian S
Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
[TBL] [Abstract][Full Text] [Related]
24. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
25. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Variants of Concern.
Choi JY; Smith DM
Yonsei Med J; 2021 Nov; 62(11):961-968. PubMed ID: 34672129
[TBL] [Abstract][Full Text] [Related]
27. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.
Alkhatib M; Salpini R; Carioti L; Ambrosio FA; D'Anna S; Duca L; Costa G; Bellocchi MC; Piermatteo L; Artese A; Santoro MM; Alcaro S; Svicher V; Ceccherini-Silberstein F
Microbiol Spectr; 2022 Apr; 10(2):e0273221. PubMed ID: 35352942
[TBL] [Abstract][Full Text] [Related]
28. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".
Meftahi GH; Jangravi Z; Sahraei H; Bahari Z
Inflamm Res; 2020 Sep; 69(9):825-839. PubMed ID: 32529477
[TBL] [Abstract][Full Text] [Related]
29. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
30. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
Zhou Z; Zhu Y; Chu M
Front Immunol; 2022; 13():898192. PubMed ID: 35669787
[TBL] [Abstract][Full Text] [Related]
31. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.
McGowan EM; Haddadi N; Nassif NT; Lin Y
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003377
[TBL] [Abstract][Full Text] [Related]
32. Chronicling the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity.
Pitsillou E; Yu Y; Beh RC; Liang JJ; Hung A; Karagiannis TC
Clin Exp Med; 2023 Nov; 23(7):3277-3298. PubMed ID: 37615803
[TBL] [Abstract][Full Text] [Related]
33. Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy.
Hamad M; AlKhamach DMH; Alsayadi LM; Sarhan SA; Saeed BQ; Sokovic M; Ben Hadda T; Soliman SSM
Viral Immunol; 2023 Mar; 36(2):83-100. PubMed ID: 36695729
[TBL] [Abstract][Full Text] [Related]
34. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
35. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern.
Ma Q; Li M; Ma L; Zhang C; Zhang H; Zhong H; Wen J; Wang Y; Yan Z; Xiong W; Wu L; Guo J; Yang W; Yang Z; Zhang B
Front Immunol; 2023; 14():1195299. PubMed ID: 37292197
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of COVID-19 pathogenesis in diabetes.
Aluganti Narasimhulu C; Singla DK
Am J Physiol Heart Circ Physiol; 2022 Sep; 323(3):H403-H420. PubMed ID: 35776683
[TBL] [Abstract][Full Text] [Related]
38. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.
Dhama K; Nainu F; Frediansyah A; Yatoo MI; Mohapatra RK; Chakraborty S; Zhou H; Islam MR; Mamada SS; Kusuma HI; Rabaan AA; Alhumaid S; Mutair AA; Iqhrammullah M; Al-Tawfiq JA; Mohaini MA; Alsalman AJ; Tuli HS; Chakraborty C; Harapan H
J Infect Public Health; 2023 Jan; 16(1):4-14. PubMed ID: 36446204
[TBL] [Abstract][Full Text] [Related]
39. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
Front Immunol; 2020; 11():588724. PubMed ID: 33117402
[TBL] [Abstract][Full Text] [Related]
40. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
